Press Releases April 30, 2026 01:03 PM

UFP Technologies to Report First Quarter 2026 Financial Results on May 4, 2026

UFP Technologies Schedules Q1 2026 Earnings Report and Conference Call

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
UFPT

UFP Technologies, a US-based contract development and manufacturing company specializing in single-use medical devices, announced it will release its first quarter 2026 financial results after market close on May 4, 2026. The company will hold a conference call the following day to discuss its performance.

UFP Technologies to Report First Quarter 2026 Financial Results on May 4, 2026
UFPT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • UFP Technologies focuses on manufacturing single-use and single-patient medical devices, supporting sectors like minimally invasive surgery and infection prevention.
  • The earnings release is scheduled after market close on May 4, with a conference call on May 5 to provide further insights to investors.
  • UFP is a key outsourcing partner to major medical device manufacturers, impacting the healthcare and medical devices sector.

NEWBURYPORT, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that the Company plans to report results for the first quarter on Monday, May 4th, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, May 5th, at 8:30 AM Eastern time.

Conference Call Information:
Date: Tuesday, May 5, 2026
Time: 8:30 AM Eastern Time

Participants may join the call using the following dial-in numbers:

  • USA/Canada: Toll-Free: 1-412-206-6478
  • International: 1-833-890-4010

A live webcast of the conference call and accompanying materials will be available here.

A replay of the webcast will be accessible following the event on the Company’s Investor Relations website at https://ufpt.com/investors/.

About UFP Technologies, Inc.

UFP Technologies is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. UFP is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. The Company’s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.

Investor Contact:                                                
Jeff Elliott
Three Part Advisors, LLC
214-966-9014

UFP Technologies Contact:
Ron Lataille, CFO
978-234-0926
rlataille@ufpt.com


Risks

  • Financial results may not meet market expectations, leading to stock price volatility in the healthcare sector.
  • Potential supply chain issues or regulatory changes affecting medical device manufacturing could impact company operations.
  • Broader market or economic conditions in the healthcare and manufacturing sectors could influence investor sentiment post-earnings.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026